Quantitative BCR-ABL test is used for the accurate quantification of BCR-ABL p210 transcripts in peripheral blood samples of Acute Lymphoblastic Leukaemia (ALL) or Chronic Myeloid (CML) patients previously diagnosed with a BCR-ABL Mbcr Fusion Gene (FG) event. The results obtained can be used to monitor efficiency of treatment in patients undergoing therapy and for Minimal Residual Disease (MRD) follow-up to monitor disease relapse.